Following on from information provided to NICE by the company in March 2019, the appraisal of Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1288 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in March 2019, the appraisal of Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 11 March 2019 | Suspended. The Department for Health and Social Care has asked NICE to conduct an appraisal of rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies. However, the company have advised that they will not be pursuing a Marketing Authorisation Application for rovalpituzumab tesirine from the European Medicines Authority for this indication at this time. This decision does not impact other Rova-T clinical studies. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if the situation changes. |
| 08 June 2018 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies. Following on from an update from the company, the timelines for this appraisal are to be confirmed. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties as and when the situation changes. |
| 06 February 2018 - 06 March 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 24 April 2017 | In progress. DH Referral Received |
For further information on our processes and methods, please see our CHTE processes and methods manual